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Abstract 
The widespread availability of genome sequencing data made possible by way of next-generation 
technologies has yielded a flood of different gene-based rare variant association tests. Most of these 
tests have been published because they have superior power for particular genetic architectures. 
However, for applied researchers it is challenging to know which test to choose in practice when little is 
known a priori about genetic architecture. Recently, tests have been proposed which combine two 
particular individual tests (one burden and one variance components) to minimize power loss while 
improving robustness to a wider range of genetic architectures. In our analysis we propose an expansion 
of these approaches, yielding a general method that works for combining any number of individual tests. 
We demonstrate that running multiple different tests on the same dataset and using a Bonferroni 
correction for multiple testing is never better than combining tests using our general method. We also find 
that using a test statistic that is highly robust to the inclusion of non-causal variants (Joint-infinity) 
together with a previously published combined test (SKAT-O) provides improved robustness to a wide 
range of genetic architectures and should be considered for use in practice. Software for this approach is 
supplied. We support the increased use of combined tests in practice-- as well as further exploration of 
novel combined testing approaches using the general framework provided here--to maximize robustness 
of rare-variant testing strategies against a wide range of genetic architectures. 
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Abstract (250 word max; currently 239) 
The widespread availability of genome sequencing data made possible by way of next-
generation technologies has yielded a flood of different gene-based rare variant association 
tests. Most of these tests have been published because they have superior power for 
particular genetic architectures. However, for applied researchers it is challenging to know 
which test to choose in practice when little is known a priori about genetic architecture. 
Recently, tests have been proposed which combine two particular individual tests (one 
burden and one variance components) to minimize power loss while improving robustness 
to a wider range of genetic architectures. In our analysis we propose an expansion of these 
approaches, yielding a general method that works for combining any number of individual 
tests. We demonstrate that running multiple different tests on the same dataset and using a 
Bonferroni correction for multiple testing is never better than combining tests using our 
general method. We also find that using a test statistic that is highly robust to the inclusion 
of non-causal variants (Joint-infinity) together with a previously published combined test 
(SKAT-O) provides improved robustness to a wide range of genetic architectures and 
should be considered for use in practice. Software for this approach is supplied. We 
support the increased use of combined tests in practice-- as well as further exploration of 
novel combined testing approaches using the general framework provided here--to 
maximize robustness of rare-variant testing strategies against a wide range of genetic 
architectures. 
Key words: next-generation sequencing; genome-wide association studies; case-control 
Introduction: 
Numerous tests of genotype-phenotype association for rare variants have been proposed, 
all of which attempt to combine signals at multiple variant sites within a gene into a single, 
powerful gene-based test of association. According to recent work, which test is most 
powerful is highly dependent upon the true genetic architecture of the phenotype 1,2. The 
challenge for the applied researcher is to know which test to choose, given limited 
information about the true genetic architecture of disease. 
A general understanding of test behavior can be obtained by noting the existence of two 
broad classes of tests (length and joint) among the many tests proposed to date1. Length 
tests (alternatively: burden, collapsing, linear; for example, CMC3) attempt to enhance the 
genotype-phenotype signal in a region of interest by collapsing variant measurements into 
a single measure of rare variant “burden,” which is then tested for association with a 
phenotype of interest. They are called length tests because they can be interpreted 
geometrically as testing for a difference in the lengths of the minor allele frequency vectors 
between cases and controls. These tests tend to be powerful when the proportion of causal 
variants is large and the effects of the causal variants are similar1. Joint tests (alternatively: 
variance components, quadratic; for example, SKAT4) combine the strength of evidence of 
individual phenotype-variant associations across the variants in a region of interest and 
tend to be powerful when there are larger proportions of non-causal variants and there is 
more variation in the effects of causal variants1. Joint tests are so named because they 
simultaneously test for differences between the lengths of the minor allele frequency 
vectors in cases and controls, as well as testing for a non-zero angle between the vectors. A 
full discussion and classification of existing tests is available elsewhere1,2. 
Recent papers have proposed combining test statistics across both the length and joint 
classes to yield more powerful test statistics 1,5–8. Results from these papers demonstrate 
how to combine a single version of a length test with a single version of a joint test5, how 
to use a weighting strategy to find the optimal weighted combination of two particular 
length and joint test statistics6, and that different weighted combinations of particular 
length and joint tests can be more powerful than single tests for different genetic 
architectures1. Overall, these combined testing approaches show improved power against a 
wider range of genetic architectures when compared to using either statistic separately 1,5–7. 
In general, any approach that combines a single length test and a single joint test will have 
a limited range of situations in which it is powerful. In particular, the combined test can 
only be powerful in cases where either of the two individual tests being combined is 
powerful. The combined test will lack power where the two tests being combined, 
simultaneously, lack power (but potentially where another, powerful, alternative test 
exists). For example, a recent paper suggested novel test statistics which may provide 
increased power when a large proportion of non-causal variants is present in the gene1, but 
current test-combining strategies have not evaluated this class of alternatives. Thus, more 
general test-combining strategies are needed in order to potentially yield more powerful 
results when the component tests being combined are powerful for a wide range of genetic 
architectures. 
 
In this paper we will demonstrate how to combine an arbitrarily large and diverse set of 
gene-based rare variant test statistics using an efficient permutation strategy. We then 
simulate a wide range of genetic architectures and evaluate the performance of two 
different methods of combining tests (Fisher’s, minimum p-value) when combined tests 
involve many different types of tests, including those using a variety of norms. We explore 
which combinations of tests are ideal and when.  
Methods 
General strategy for combining tests 
We propose the following approach for combining p-values from k different gene-based 
rare variant tests. For a gene of interest, calculate 𝒇+and 𝒇−, where 𝒇+ is a vector of 
observed allele frequencies, (𝑓1
+, 𝑓2
+, … , 𝑓𝑚
+), in the cases, across the m variant sites in the 






+indicate the total number of minor alleles in the cases 
at site j, and 𝑁+ be the number of cases in the sample. Vector 𝒇− holds similar definitions 
for the controls. 
After computing 𝒇+and 𝒇−, find the p-value for each of the k different gene-based rare 
variant tests, yielding a vector of p-values, p=(𝑝1, 𝑝2, … , 𝑝𝑘), for each gene of interest (see 
Rare variant tests section for details). The vector p is used to generate a test statistic, 
Sk=f(p), which summarizes the strength of evidence across p; essentially, the combined 
strength of evidence of genotype-phenotype association across the entire set of k tests. We 
consider two different ways of computing Sk. The first is the Fisher’s combined p-value 
test statistic and is computed as Fk= ∑ −2log⁡(𝑝𝑖)
𝑘
𝑖=1 . We note that if the k tests were 
mutually independent, the distribution of Fk would follow a chi-squared distribution; 
however, that is likely not the case in practice. Instead, we assess significance of Fk using 
the permutation strategy described in the following section. 
The second summary statistic is the minimum p-value, Min(p), with significance assessed 
using the permutation strategy described in the following section. For comparison, we also 
compute significance of the Min(p) statistic using a Bonferroni correction approach where 
the summary statistic is deemed significant if Min(p) is less than 𝛼/𝑘, for some a priori 
specified 𝛼. 
Description of the permutation strategy 
For a general univariate summary statistic Sk of vector p (in our case either Fk or Min(p)), 
statistical significance can be assessed by permuting phenotype status, performing k tests 
on the permuted data, recomputing Sk on each permutation, and calculating the percent of 
times that permuted values of Sk are greater than the observed Sk.  Recently
5, an efficient 
permutation strategy for assessing the significance of a test Sk with k=2 (one length and one 
joint) test was proposed. We extend the approach for any number of gene-based tests k of 
any type. The extended approach is to: (1) Calculate the observed value of Sk as a function 
of p, where p is the vector of p-values for each of the i=1,…,k tests being combined. (2) 
Permute the phenotype and re-compute test statistics, 𝑡𝑖
∗(𝑙), under permutation for each of 





∗(𝑃)), a vector of permuted test statistics for test i. Note: These are the 
same P permutations for all tests. (3) Calculate 𝑅𝑎𝑛𝑘(𝑡𝑖
∗(𝑙)), the rank of each of the test 
statistics in vector 𝑡𝑖
∗ for each of the i=1,…,k tests, where 𝑅𝑎𝑛𝑘(𝑡𝑖
∗(𝑙)))=1 for the largest 
value of  𝑡𝑖
∗(𝑙) and Rank(𝑡𝑖
∗(𝑙)))=P for the smallest value of 𝑡𝑖
∗(𝑙). (4) Calculate an 
empirical p-value for each of the permuted test statistics as 𝑝𝑖
∗(𝑙) = 𝑅𝑎𝑛𝑘(𝑡𝑖
∗(𝑙))/P. (5) An 
empirical null distribution (no genotype-phenotype association) for S is computed by 
calculating the value of Sk(l) from the vector of p-values 𝒑∗(𝒍) = (𝑝1(𝑙), 𝑝2(𝑙),… , 𝑝𝑘(𝑙)), 
for each permutation l=1,…,P. (6) The significance of Sk is computed by calculating the 
percentage of Sk(l) values that are larger than Sk, out of the set of P phenotype 
permutations.  
A few additional comments are worthwhile. First, the procedure can be modified in a 
straightforward manner for two-sided tests (either individual or combined), by looking at 
both tails of the empirical null distribution of statistics. Second, for individual tests based 
on asymptotic distributions, steps (3) and (4) are merely replaced by using the asymptotic 
distribution to calculate the 𝑝𝑖(𝑙). Finally, and importantly, we note that the use of the 
same P permutations in step (5) is needed in order to properly model the correlation 
structure between tests and generate an appropriate null distribution for Sk.  
Rare variant tests 
We explored combinations of different gene-based rare variant tests which were selected to 
represent a variety of different approaches for evaluating genotype-phenotype associations. 




 as the p-norm for a vector 𝒙 = (𝑥1, 𝑥2, … , 𝑥𝑚). The 
individual rare variant tests we considered were: (1) Sequence Kernel Adaptive Test 
(SKAT) 4. SKAT is essentially equivalent to 𝑄𝑆 = ‖𝒇
+ − 𝒇−‖2
1 with an asymptotic 
distribution used for statistical significance-- a joint test using the 2-norm. (2) Combined 
Multivariate and Collapsing Test (CMC)3. When all variants are collapsed, CMC can be 
viewed as essentially equivalent to 𝑄𝐵 = ‖𝒇
+‖1 − ‖𝒇
−‖1
1 with significance assessed using 
an asymptotic distribution-- a length test using a 1-norm. In our analysis we collapsed all 
variants because our simulations focused on variants with population minor allele 
frequency less than 1%. (3) Sequence Kernel Adaptive Test-Optimal (SKAT-O) 6,7. SKAT-O 
combines SKAT and a general burden test (CMC) by the optimal weight ρ, such that  𝑄ρ =
ρ𝑄𝐵 + (1 − ρ)𝑄𝑆 yields the minimum p-value and uses an asymptotic distribution to 
assess statistical significance. (4) Length tests with different norms (L(p)) 1, which test for 
differences in the lengths of the minor allele frequency vectors between cases and controls. 
We considered four versions of length tests of the form 𝐿(𝑝) = ‖𝒇+‖𝑝 − ‖𝒇
−‖𝑝, with 
significance assessed via phenotype permutation. The four versions were generated by 
considering different values of the norm, p, p=1, 2, 4 and ∞, where ‖𝒙‖∞ = max (abs(xi)). 
(5) Joint tests with different norms (J(p)) 1, which simultaneously test for differences in the 
lengths and for a non-zero angle between the two allele frequency vectors. We considered 
four versions of joint tests of the form 𝐽(𝑝) = ‖𝒇+ − 𝒇−‖𝑝, with significance assessed via 
phenotype permutation. We used four different values of p, p=1, 2, 4 and ∞.  Higher 
normed tests are more robust to the inclusion of non-causal variants1. Thus, we considered 
a total of 11 individual gene-based variant tests (SKAT (a 2-norm joint test), SKAT-O (a 
combined test), CMC (a 1-norm length test), L(1), L(2), L(4), L(∞), J(1), J(2), J(4), J(∞). 
We then combined subsets of the 11 individual gene-based rare tests using both the 
Fisher’s and Min(p) approaches (see Methods: General strategy for combining tests 
section). The 8 different combinations of tests we considered were: (1) Length tests with 
different norms (L(1), L(2), L(4), L(∞)) (CT1), (2) Joint tests with different norms (J(1), 
J(2), J(4), J(∞)) (CT2),(3) Similar length tests (CMC, L(1)) (CT3), (4) Similar joint tests 
(SKAT, J(2)) (CT4), (5) Typical length-joint combined test (SKAT, CMC) (CT5), (6) 
Length and joint tests across norms (L(1), L(2), L(4), L(∞),(J(1), J(2), J(4), J(∞)) (CT6), 
(7) Length and joint with some norms (L(1), L(4), J(1), J(4) (CT7), (8) More robust SKAT-
O (SKAT-O, J(∞)) (CT8). A brief rationale for the inclusion of each test is provided in 
Table 1. 
Simulations 
We conducted two main simulation studies as part of our analysis. In the first simulation, 
we explored the general behavior of the Fisher’s and Min(p) approaches across a variety of 
different numbers of tests, correlation structures and power settings using generalized 
gene-based test statistics. In the second simulation we simulated data according to a priori 
specified genetic disease models and applied the gene-based rare variant tests of 
association described in the previous section. 
Simulation #1: Investigating the behavior of Min(p) and Fisher’s 
Data was simulated from multivariate normal random variables, T~𝑀𝑉𝑁(𝝁, 𝜮) (MVN = 












 . Each multivariate normal sample represents a vector 
of test statistics, T, from k different gene-based rare variant tests, where H0: 𝝁 = 𝟎, Ha: at 
least one of 𝜇1, 𝜇2, … , 𝜇𝑘 > 0⁡and 𝜌𝑖,𝑗 is a measure of correlation between tests i and j. We 
consider all possible combinations of the following parameters: (1) Number of tests, k, 
equal to 2, 4, 6, 10 and 20 (2) 𝜌𝑖,𝑗 = 0, 0.25, 0.50, 0.75, 0.90 and 0.99 between the test 
statistics of two tests i,j. Note: we specified the correlation 𝜌 between test statistics, 
however the corresponding correlations between p-values are quite similar (details not 
shown). (3) (a) H0: 𝝁 = (𝜇1 = 0, 𝜇2 = 0,… , 𝜇𝑘 = 0)  (b) An Ha where all tests perform 
equally well: 𝝁 = (𝜇1 = 2, 𝜇2 = 2,… , 𝜇𝑘 = 2). We note that the approximate power of 
each individual test, i, under the alternative hypothesis (𝜇𝑖 = 2) is equal to 
𝑃(𝑍 > 𝑧𝛼 − 𝜇𝑖) = 𝑃(𝑍 > −0.355) = 0.64, where Z ~ Normal(0,1) at a significance level 
of 5% (𝑧𝛼 = 1.645) for a one-sided upper-tailed test, representing a moderately powered 
test. We also considered lower significance levels of 0.01, 0.001 and 0.0001, which yield 
individual test power of 37%, 14% and 4%, respectively. 
After generating 10,000 multivariate normal random samples for each combination of 
simulation parameters, we computed the p-value of each test statistic, Ti, for each of the 
10,000 samples, by finding 1 − 𝜙(𝑇𝑖) where 𝜙() is the cumulative distribution function 
(CDF) of a standard, normal distribution. We then applied Min(p) and Fisher’s methods to 
each set of p-values, with significance assessed by comparing alternative hypothesis values 
of Min(p) and Fisher’s statistics to the simulated distributions of these statistics under the 
null hypothesis. The power of each approach (Min(p) and Fisher’s) for each simulation 
setting is estimated by dividing the fraction of significant (α=0.05, 0.01, 0.001 or 0.0001) 
statistics by 10,000 (the number of independent samples). We then conducted a follow-up 
simulation in which we varied the number of tests, k (k=2, 4, 6, 10 and 20), fixed 𝜌𝑖,𝑗 = 0 
between two tests i,j and then varied the number of tests for which 𝜇𝑖 = 2 from 1 to 10, 
with the remaining tests having 𝜇𝑖 = 0. Full results from these simulations, which include 
observed correlations between p-values for all settings illustrating the approximately 
equivalent correlations between test statistics and p-values, are available in Supplemental 
Tables 1a-1c. 
Simulation #2- Investigating the behavior of combinations of gene-based rare variant tests 
across different genetic disease models 
We simulated data to represent a variety of different genetic disease models. In all 
simulations, we considered a sample size of 2,000 individuals split evenly between cases 
and controls. We then simulated data across all possible combinations of the following 
parameters: (1) Number of single nucleotide variants (SNVs) (32 or 64) (2) Proportion of 
non-causal SNVs (0, ¼, ½, ¾, 7/8, 15/16, 31/32, 63/64, 1) (3) Proportion of causal SNVs 
that increase disease risk (0, ¼, ½, ¾, 1), with the remaining causal SNVs causing a 
decline in disease risk (4) Relative risk of causal, risk-increasing SNVs (1.1, 1.5 and 2.0). 
To investigate impact on test performance in the presence of risk-reducing SNVs, some 
simulation settings included risk-reducing SNVs with relative-risk 0.5. Furthermore, SNV 
minor allele frequencies were simulated in a three to one ratio of less common (0.1% 
population minor allele frequency) to more common (1% minor allele frequency) SNVs 
spread evenly across all non-causal and causal SNVs. We note that when the number of 
SNVs is not divisible by 4, a single 1% minor allele frequency SNV is assigned before 
generating up to 3 additional 0.1% minor allele frequency SNVs. Thus, there were a total 
of 2 (number of SNVs) x 9 (proportion of non-causal) x 5 (proportion of risk increasing 
SNVs) x 3 (relative risk of risk increasing SNVs) settings, of 270 possible simulation 
settings. However, some of the combinations are redundant or impossible; removing these 
cases yields 197 total simulation settings considered in our analysis.  
Five-hundred samples were generated at each simulation setting, with each of the 20 
individual tests and each of the 11 combined tests applied to each sample, and separate p-
values for Min(p) (permutation p-value) and Fisher’s for each combined test. Empirical 
power estimates are computed as the percentage of p-values less than 0.05 (nominal alpha), 
giving power estimates within 2√
0.5(1−0.5)
500
≈ 4% of the true power 95% of the time. For 
the Bonferroni testing approach, we deem the test significant if at least one of the 
individual test p-values in the set is below the Bonferonni correct alpha value of 0.05/k. 
Where needed, 500 permutations were used to assess statistical significance for individual 
and combined tests.  
To further explore test performance at significance levels commonly used in practice, 
additional simulations were conducted. In particular, 16 of the settings described above 
were investigated using 50,000 permutations at significance levels of 10-4, 10-3 and 10-2. 
Fourteen of these settings represented situations in which causal variants were present (32 
total SNPs with 1,2 or 4 causal variants; 64 total SNPs with 1,2,4 or 8 causal variants), 
where all causal variants have RR=2 (7 cases) or 3 (7 cases); 200 simulations were 
conducted at each setting. Two settings represented situations in which no causal variants 
were present (32 total SNPs and 64 total SNPs), and used 840 and 460 total simulations at 
each setting, respectively. 
Application 
As a proof of concept, we applied select gene-based tests to data from Genetic Analysis 
Workshop 17. The data consists of real genotype data (from the 1000 Genomes Project 
consortium) on which a disease phenotype was simulated10. We considered 25 genes which 
were known to contain causal variants for the simulated disease phenotype and showed 
variation in the sample of n=321 unrelated Asian subjects. Given the small sample size and 
low power in this dataset5, final disease status for each of the 321 individuals was averaged 
across 200 independent phenotype simulations, with individuals who were diseased in at 
least 100 of the 200 independent simulations identified as ‘diseased,’ and the rest not. As 
has been done previously5, we used a significance level of 0.05 for this analysis. 
Results 
General patterns in the performance of Min(p) and Fisher’s methods (Simulation #1) 
We start by exploring the general behavior of Min(p) and Fisher’s method across a generic 
set of k tests, with different correlation structure and test performance (Simulation #1 
described earlier). The goal of this analysis is to provide an intuitive sense of how the 
number of tests, correlation between tests and individual test performance is related to the 
performance of Min(p) and Fisher’s method in a well-understood environment. Detailed 
simulation results are provided in Supplemental Tables 1a-1c. Supplemental table 1a 
illustrates that the type I error rate is controlled across all simulation settings and 
significance levels. 
When all tests are powerful 
When all tests being combined have good power (64% at 𝛼 = 0.05), both the Fisher’s and 
Min(p) approaches yield increased power as the number of tests being combined increases. 
However, Fisher’s method tends to outperform Min(p), with the magnitude of the power 
gain for Fisher’s relative to Min(p) decreasing as the correlation between tests increases, 
and the power of combined, highly correlated tests equal to the power of a single test-- 
approximately 64% (see Supplemental Table 1b and Figure 1). In situations where all tests 
are powerful, Min(p) ignores the power from all the tests but one, forgoing the opportunity 
to improve the power by combining tests and yielding lower power overall as compared to 
Fisher’s approach. Similar results are observed for other significance levels. 
When some tests are powerful 
When we varied the number of powerful (good) tests (power=64% at 𝛼 = 0.05) and 
under-powered (bad) tests (power=5%=type I error rate) we found that Min(p) outperforms 
Fisher’s if there is only one good test in the set, with the magnitude of improvement 
increasing as the number of bad tests increases (for example, see Figure 2, similar results 
are observed for other significance levels, see Supplemental Table 1c.). When there are two 
good tests in the set, Fisher’s does better when there are few bad tests, but as more and 
more bad tests are added to the set, Min(p) gains an advantage over Fisher’s. In general, 
Min(p) outperforms Fisher’s when the proportion of bad tests in the set is large. The 
impact of correlation between tests on these relationships can be inferred from the previous 
section.  
Performance of combined tests on simulated phenotype-genotype data (Simulation #2) 
Type I error simulation 
The type I error simulation showed general control of the type I error rate across all 
individual tests and combined tests considered here, with the lone exception being the 
Bonferroni method, which was, as expected, often conservative. Detailed Type I error 
simulation results are in Supplemental tables 2a and 2b. Additional simulations at lower 
significance levels (1x10-2, 1x10-3, 1x10-4) also showed control of the type I error rate in all 
cases (detailed results not shown). 
Min(p) beats Bonferroni every time 
Across the 197 simulation settings and 8 combined tests (1576 possibilities; see 
Supplemental Table 3), as well as all follow-up simulations at lower significance levels, 
there were only 10 times where power of the Bonferroni approach exceeded the power of 
the Min(p) approach, doing so only minimally (ranging from 0.002 to 0.004); well within 
the range of expected variation due to simulation. Thus, it is safe to conclude that Min(p) 
will always be better than Bonferroni. We do not consider the Bonferroni approach in 
subsequent analyses. 
Improving a combined test with additional tests 
We explored 8 different combined tests. Rationale and summaries of performance are 
provided in Table 1. In general, the results of the second simulation study confirmed 
results of the first simulation study with regards to the use of Min(p) or Fisher’s and how 
many tests to combine. In short, (1) combining tests that are powerful in different 
situations will generally be advantageous (e.g., CT6, CT7 and CT8), (2) Min(p) 
outperforms Fisher’s combining method when there is a mix of powerful and non-powerful 
tests being combined (e.g., CT5, CT6, CT7) and (3) combining highly correlated tests has 
little benefit (e.g., CT2, CT3, CT4). These results held true even at lower significance 
levels (see Supplemental Table 4) 
Robust test statistic 
As shown in Table 1, CT8 yielded the best overall performance, with the Fisher’s method 
performing slightly better than the Min(p) method across all simulation settings; CT6 and 
CT7 also performed quite well. Across the 197 simulation settings, CT8 (combination of 
SKAT-O and J(∞)) yielded power no more than 5% smaller than SKAT-O power in 87.3% 
(Fisher’s; 172/197) and 83.2% (Min(p); 164/197) of simulation settings. The power of CT8 
was never worse than 10% less than SKAT-O power. However, the combined test was 
sometimes substantially better than SKAT-O, as shown in Table 2. In particular, since J(∞) 
is robust to the inclusion of high proportions of non-causal variants, CT8 is more robust to 
the inclusion of non-causal variants than SKAT-O alone. J(∞), however, performs more 
poorly than SKAT-O and most other tests when the proportion of causal variants in a gene 
is moderate (see Supplemental Table 3, which provides the full results for all simulation 
settings, for details). Finally, Figures 3 and 4 illustrate the performance of the methods at a 
low significance level, showing similar results at a relative risk of 2. We note that the 
power is not very high in this case. Supplemental figures 2 and 3 illustrate the same 
performance using a relative risk of 3, yielding larger power. 
The performance of the Fisher’s combination approach was generally better than 
the Min(p) approach of CT8 as shown in Tables 1 and 2. In a head to head comparison, the 
Fisher’s approach yielded  better power than the Min(p) approach in more than twice as 
many simulations (119 vs. 45 settings), though power gains were only modestly better 
(average power gain 1.8% vs. 1%), with a max power difference of only 5.2%. Table 2 
also illustrates the relatively good performance of CT6 and 7 in this subset of simulation 
settings.  
Application to data from Genetic Analysis Workshop 17 
The p-values for four tests (SKAT-O, J(∞)) and both the Fisher’s and Min(p) versions of 
CT8) which were applied to 25 genes containing at least one causal variant are provided in 
Supplemental Table 5.  Six genes are significant (p<0.05) using SKAT-O alone and four 
genes are significant using J(∞) alone (three genes are significant using both approaches), 
for a total of seven genes identified by at least one of the two individual testing methods.  
The Min(p) version of CT8 identified all seven of the genes as significant and Fisher’s 
identified five of the seven as significant, while the remaining two were borderline 
significant (p<0.07), demonstrating that the combined methods are robust. In particular, we 
note that the PIK3C3 gene was significant using the J(∞) approach (p=0.035), but not 
SKAT-O (p=0.056), and was significant for both combined tests (Min(p) p-value=0.041, 
Fisher’s p-value=0.035).  
Software 
Software written for R9 is available for free download on the research group’s software 
page (http://www.dordt.edu/academics/programs/math/statgen/software.shtml).  All 
individual and combined tests considered here are included. 
 
Discussion 
We have proposed a general and flexible method for combining different rare variant tests 
of association to potentially improve robustness across a wide range of genetic 
architectures while minimizing power loss through the addition of multiple tests. A naïve 
approach to combining tests is to use a Bonferroni correction after applying multiple 
different rare variant tests to the same data. However, Bonferroni is often conservative, 
especially when tests being combined are correlated, and we demonstrated that the Min(p) 
approach is always more powerful because it empirically estimates the appropriate 
correlation structure. Thus, in practice, researchers should never run multiple (k>1) gene-
based tests on the same dataset and then apply a stricter Bonferroni correction strategy 
(α/(k*genes)) to their dataset. The Min(p) approach proposed here will always be more 
powerful than such an approach. 
We also showed that while the Min(p) approach is sometimes optimal, the Fisher’s 
method offers advantages over Min(p) in some cases because it combines separate signals 
into a combined signal when tests are well-powered and the correlation between tests is 
low. However, we’ve shown that when combining tests with lower power, Min(p) 
improves to the point of being better than Fisher’s method in some cases. In short, Min(p) 
ignores the ‘noise’ of low powered tests, while Fisher’s averages low powered tests into 
the signal. Furthermore, as the correlation between well-powered tests increases, Min(p) 
also gains power relative to Fisher’s. Ultimately, the answer to whether Min(p) or Fisher’s 
provides more power is dependent upon the underlying power and correlation structure of 
the tests being combined. However, combining highly correlated tests is not advantageous 
either. The most benefit is obtained by combining disparate tests-- as we illustrated by 
combining J(∞) with SKAT-O--to yield a more robust and powerful test. Across 
simulation settings considered here the Fisher’s approach for the SKAT-O/ J(∞) combined 
test was somewhat more robust than the Min(p) approach and so is recommended for use 
in practice. 
More broadly than either Min(p) or Fisher’s, our method is flexible enough to 
consider any of the numerous other choices for Sk, which is simply a function of the vector 
of p-values from the k-tests being combined, p=(𝑝1, 𝑝2, … , 𝑝𝑘). We have focused on 
Fisher’s and Min(p) because they represent two extreme approaches: Fisher’s is a weighted 
average of all the p-values, and Min(p) only uses a single value from the vector. 
Furthermore, both approaches are popular since, when tests are independent, each has 
fairly well understood asymptotic properties. More research is needed to explore additional 
possibilities. We note that while we restricted our analysis to case-control study designs, 
the results are directly applicable to results for quantitative traits. 
A key advantage to the combined testing approach comes when evaluating multiple 
genes and/or multiple phenotypes. In these cases, a priori, there may be little information 
about which individual test is most powerful given the wide range of potential genetic 
architectures. The best test strategy will be one which provides an optimal tradeoff of 
power loss and robustness. Namely, for any particular genetic architecture, an individual 
test can be constructed with better power than any combined test. However, individual 
tests may be powerful against only a small set of genetic architectures. Thus, a combined 
test may trade off (vs. an individual test) small amounts of power against some genetic 
architectures for large improvements in power versus other genetic architectures. 
One area of application we have explored is the straightforward application of our 
approach to gene-based rare variant tests that use thresholds (e.g., CMC3 which thresholds 
on Minor Allele Frequency, or the Odds Ratio Weighted Sum Statistic11 with thresholds on 
empirical odds ratio) to generate variable threshold tests in a straightforward manner. In 
short, simply combine the same test across multiple thresholds to yield an optimally robust 
test (detailed results not shown).  
With this in mind, how should a researcher utilize combined tests in practice? Prior 
work5–7 has shown that combined tests can be considered ‘optimal,’ however, these 
approaches have been limited to combining L(1) and J(2) tests. In this paper we have 
shown that combining other disparate tests can be advantageous (e.g., combining SKAT-O, 
itself a combination of L(1) and J(2), with J(∞)). For example, we showed that the 
inclusion of a higher norm test can provide increased robustness to the inclusion of non-
causal variants. In practice, we recommend including J(∞) in a combined test with L(1) 
and J(2) (e.g., SKAT-O with J(∞)) to maximize robustness to the inclusion of non-causal 
variants in cases where little prior knowledge exists to prioritize potential causal SNPs 
and/or it is anticipated that a high proportion of SNPs included in the test may be non-
causal. However, further analysis of simulated data with larger sample sizes, additional 
variation in causal variant risk distribution, etc., and which builds on our analysis of real 
genotype data from Genetic Analysis Workshop 17, is warranted. This exploration is 
especially needed given recent results yielding moderately sized relative risks, even for 
rare variants, in practice.  
Conclusions 
Combined testing approaches offer a general and appealing alternative to individual, gene-
based rare variant tests of association which may be optimized only for particular genetic 
architectures. We have demonstrated that the loss of power from the addition of one or two 
disparate tests may be offset by improved power for a wider range of genetic architectures. 
We also identified a particular combined test with good properties. As additional, novel, 
rare-variant tests are developed they should be evaluated for possible combination with 
existing tests to yield maximally robust testing approaches. 
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Figure 1. Power of combined testing approaches as the correlation between powerful 
tests increases.  
 
All k tests being combined have individual power of 64.5% at a significance level of 0.05. 
When combining multiple powerful tests, and no tests with low power, the Fisher’s method 
is always more powerful than the Min(p) method since all tests contribute to the power of 
the combined test for Fisher’s method, but only a single test contributes to the Min(p) 
approach. As the correlation between powerful tests increases all combined tests converge 
to the power of a single test (64.5%). In general, combining more powerful tests increases 
power. Similar patterns are observed with lower significance levels (see Supplemental 
Tables 1a-1c). 
  
Figure 2. Power of combined testing approaches as the number of poorly performing 
tests increases 
Of the k tests being combined either 1, 2 or 4 tests are ‘good’ (having power = 64.5%), 
while the remainder perform poorly (power = 5%, the type I error rate). When there is only 
one powerful test, the Min(p) method outperforms Fisher’s method, but when there are 
four ‘good’ (powerful) tests, Fisher’s test outperforms Min(p). The breakeven point is 
shown when there are two good tests and we see that Fisher’s is better when there are 10 or 
fewer tests, but Min(p) is better when there are 20 total tests being combined. This figure 
only illustrates cases where there is no correlation between tests. The impact of correlation 
between tests can be inferred from Figure 1. Similar patterns are observed with lower 
significance levels (see Supplemental Tables 1a-1c). 
  
Figure 3. Power of single and combined gene-based rare variant tests (32 SNVs) 
Power of five different tests (3 individual and 2 combined) in the presence of high 
percentage of non-causal variants and at a significance level of 1x10-4. The relative risk of 
the causal SNVs in the set of 32 SNVs is 2, with 1000 cases and 1000 controls. The 
combined test using either the Min(p) or Fisher’s approaches is a robust alternative to 
individual tests. 
 
Figure 4. Power of single and combined gene-based rare variant tests (64 SNVs) 
Power of five different tests (3 individual and 2 combined) in the presence of high 
percentage of non-causal variants and at a significance level of 1x10-4. The relative risk of 
the causal SNVs in the set of 64 SNVs is 2, with 1000 cases and 1000 controls. The 
combined test using either the Min(p) or Fisher’s approaches is a robust alternative to 
individual tests.  















variants and tradeoff 
with number of tests 
combined 












variants and tradeoff 












Assess impact of 
combining highly 
correlated tests 























Assess a ‘standard’ 
combination of tests 
0.46 Fairly 
robust 
Lacks robustness to 













variants and tradeoff 

















variants and tradeoff 






Fisher’s performs a 








Assess ability to 








Slightly lower power 







1. Average pairwise correlation across all pairs of tests in the combined test. See 
Supplemental Figure 1 for complete matrix of pairwise correlations. 
2. Percent of simulations in which method had at least 5% lower power than other methods. 
Table 2. Power of common gene-based rare variant tests and novel combined tests across select settings 
   Power 































32 (2) 0 1 1 1 0.99 1 1 1 1 1 1 
16 (2) 0 0.85 0.97 0.988 0.926 0.988 0.994 0.99 0.996 0.986 0.984 
8 (2) 0 0.346 0.786 0.774 0.784 0.82 0.872 0.808 0.866 0.798 0.83 
4 (2) 0 0.122 0.416 0.338 0.548 0.506 0.52 0.44 0.428 0.504 0.502 
2 (2) 0 0.086 0.368 0.304 0.5 0.454 0.462 0.424 0.408 0.472 0.466 
1 (2) 0 0.1 0.392 0.322 0.514 0.488 0.53 0.442 0.432 0.478 0.496 





16 (2) 0 0.986 0.99 0.996 0.944 0.996 0.998 0.994 0.996 0.994 0.996 
8 (2) 0 0.632 0.8 0.816 0.772 0.83 0.88 0.82 0.872 0.812 0.824 
4 (2) 0 0.206 0.546 0.526 0.602 0.602 0.622 0.574 0.586 0.584 0.596 
2 (2) 0 0.194 0.49 0.446 0.59 0.51 0.56 0.51 0.504 0.548 0.574 
1 (2) 0 0.132 0.494 0.426 0.58 0.554 0.58 0.52 0.528 0.536 0.558 





24 (1.1) 8 (0.5) 0.066 0.322 0.266 0.22 0.256 0.214 0.268 0.212 0.266 0.29 
18 (1.1) 6 (0.5) 0.082 0.336 0.25 0.234 0.234 0.188 0.242 0.2 0.248 0.288 
12 (1.1) 4 (0.5) 0.05 0.184 0.134 0.134 0.122 0.114 0.126 0.108 0.154 0.164 
6 (1.1) 2 (0.5) 0.074 0.16 0.12 0.152 0.108 0.104 0.118 0.108 0.126 0.148 
3 (1.1) 1 (0.5) 0.074 0.152 0.126 0.144 0.132 0.13 0.136 0.122 0.138 0.146 





48 (1.1) 16 (0.5) 0.108 0.518 0.418 0.248 0.348 0.302 0.362 0.35 0.364 0.392 
36 (1.1) 12 (0.5) 0.068 0.404 0.322 0.24 0.3 0.27 0.312 0.288 0.302 0.314 
24 (1.1) 8 (0.5) 0.052 0.254 0.208 0.19 0.2 0.162 0.204 0.174 0.214 0.232 
12 (1.1) 4 (0.5) 0.048 0.134 0.116 0.116 0.1 0.11 0.102 0.108 0.126 0.132 
6 (1.1) 2 (0.5) 0.07 0.086 0.07 0.086 0.078 0.078 0.072 0.08 0.07 0.088 
3 (1.1) 1 (0.5) 0.05 0.1 0.078 0.11 0.078 0.078 0.08 0.066 0.092 0.104 
Bold indicates tests that are within 5% of optimal for single tests or within 5% of optimal for combined tests. 
1RR=Relative risk of causal variants 
 
Supplementary Materials 
Supplemental Figure 1 – Correlation between p-values of different tests is considered across different genetic architectures. 
Joint tests and SKAT like tests are highly correlated, as are Length and CMC tests.  
Supplemental Figure 2 - Power of five different tests (3 individual and 2 combined) in the presence of high numbers of non-
causal variants and at a significance level of 1x10-4. The relative risk of the causal SNVs in the set of 32 SNVs is 3, with 1000 
cases and 1000 controls. The combined test using either the Min(p) or Fisher’s approaches is a robust alternative to individual 
tests. 
Supplemental Figure 3 - Power of five different tests (3 individual and 2 combined) in the presence of high numbers of non-
causal variants and at a significance level of 1x10-4. The relative risk of the causal SNVs in the set of 64 SNVs is 3, with 1000 
cases and 1000 controls. The combined test using either the Min(p) or Fisher’s approaches is a robust alternative to individual 
tests. 
Supplemental Tables 1a, 1b and 1c – Simulation results for null hypothesis (Table 1a), alternative hypothesis (Table 1b) and 
mixed hypothesis (Table 1c) situations involving generic combinations of two or more gene-based rare variant tests with 
different correlations and power and using different test combination strategies, across four different significance levels. 
Supplemental Table 2a and 2b – Type I error rates of individual and combined tests across a variety of simulation settings. Type 
I error rates are generally maintained. 
Supplemental Table 3- The power of each combined and individual test for all 197 simulation settings  
 
Supplemental Table 4 – The power of combined and individual tests at lower significance levels 
 
Supplemental Table 5- The p-values of four different gene-based rare variant tests on 25 genes from GAW17 
 
 
